Technology
Health
Biotechnology

Vascular Biogenics

$1.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-1.54%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell VBLT and other stocks, options, ETFs, and crypto commission-free!

About

Vascular Biogenics Ltd. Ordinary Shares, also called Vascular Biogenics, is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. Read More It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Employees
Headquarters
Modi'in, Jerusalem
Founded
2000
Market Cap
45.93M
Price-Earnings Ratio
Dividend Yield
Average Volume
158.92K
High Today
$1.33
Low Today
$1.24
Open Price
$1.29
Volume
4.50K
52 Week High
$3.10
52 Week Low
$0.60

Collections

Technology
Health
Biotechnology
Cancer Prevention
Medical
Biopharmaceutical
Pharmaceutical
2014 IPO

News

Yahoo FinanceMay 8

Will Vascular Biogenics (VBLT) Report Negative Earnings Next Week? What You Should Know

Vascular Biogenics (VBLT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

63
Yahoo FinanceMay 6

VBL Therapeutics to Report First Quarter 2019 Financial Results on May 15

TEL AVIV, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Wednesday, May 15 at 8:30am Eastern Time to report first quarter ended March 31, 2019 financial results and to provide a corporate update.

22

Earnings

-$0.24
-$0.08
$0.08
$0.24
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.12 per share
Actual
-$0.12 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.